Updated
Benitec BiopharmaBNTC · Healthcare
$9.54+10.42%
Market cap$328M
IndustryBiotechnology
Benitec Biopharma (BNTC) Superinvestor holders
3 of the superinvestors we track hold Benitec Biopharma (BNTC) in their latest 13F filings, $21M in total.
Summary
The largest holder is Wilmot Harkey (Nantahala Capital Management), with $20M, 1.2% of the portfolio.
In their latest quarter: 1 opened a new position, 1 added.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Wilmot Harkey Nantahala Capital Management |
Added | 1,488,371 | $20M | 1.2% | Q2 2026 |
| Didric Cederholm Lion Point Capital |
Held | 62,000 | $829,560 | 4.0% | Q2 2026 |
| Cliff Asness AQR Capital Management |
New position | 22,481 | $300,796 | 0.0% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 3 |
| Q1 2026 | 4 |
| Q4 2025 | 3 |
| Q3 2025 | 2 |
| Q2 2025 | 4 |
| Q1 2025 | 3 |
| Q4 2024 | 2 |
| Q3 2024 | 2 |
Questions about Benitec Biopharma
Which superinvestors own Benitec Biopharma?
3 of the superinvestors we track hold Benitec Biopharma (BNTC) in their latest 13F filings, $21M in total. Wilmot Harkey, Didric Cederholm, Cliff Asness.
Who is the largest superinvestor holder of BNTC?
The largest holder is Wilmot Harkey (Nantahala Capital Management), with $20M, 1.2% of the portfolio.
From Benitec Biopharma's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.